FDA Peptide Update July 2026: BPC-157, TB-500, 503A Bulks List & Compounding

July 2026 brought two major FDA peptide regulatory actions, but they addressed completely different issues. On July 23-24, the Pharmacy Compounding Advisory Committee (PCAC) reviewed seven unapproved peptides for potential inclusion on the Section 503A Bulks List. On July 28, the FDA issued separate draft guidance covering generic versions of already approved peptide and protein drugs. The seven peptides reviewed were BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide. Six received recommendations for inclusion, while Emideltide was rejected. Importantly, each vote applied to a specific medical indication. BPC-157, for example, was evaluated for ulcerative colitis, not for the tendon and joint applications commonly discussed online. The advisory vote did not make BPC-157, TB-500, or the other peptides FDA-approved, nor did it immediately authorize their compounding. None had been added to the Section 503A Bulks List. The recommendations are non-binding, meaning further FDA action is still required. FDA scientists opposed all seven peptides, citing limited human clinical evidence, potential immunogenicity and anaphylaxis risks, and difficulties establishing consistent substance identity and manufacturing standards. The regulatory history goes back to 2023, when the substances were placed in Category 2 because of significant safety concerns. Their removal from Category 2 in April 2026 made them eligible for evaluation but did not authorize compounding. The separate July 28 FDA action concerned generic versions of approved peptide and protein drugs. The agency published 17 revised draft product-specific guidances covering nine active ingredients, including semaglutide, tirzepatide, liraglutide, and teriparatide. These guidances address generic drug development and do not create a regulatory pathway for unapproved peptides. For anyone following BPC-157, TB-500, peptide compounding, FDA peptide regulation, or the 503A Bulks List, the key distinction is simple: an advisory recommendation is not FDA approval, and generic drug guidance is not authorization for unapproved peptides. You can read the full article and FDA news and updates at: https://www.onpeps.com/blog/fda-peptide-update-july-2026